Pay in 4 interest-free payments of $11.25 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
Bortezomib or Imatinib for synergistic activity
is a potent ErbB inhibitor for the treatment of cancer
visible nuclei and more noticeable bile canaliculi between hepatocytes
Apoptosis Activator 2 is a potent and selective carboxylesterase inhibitor with Ki of 67/31/65 nM for hiCE/hCE/rCE respectively
Molecular Weight: 719
AG-120 (Ivosidenib) - IDH1 Inhibitor. CAS# 1448347-49-6 Catalog No.:M60318-10S Bortezomib or Imatinib for synergisticAG 120 (Ivosidenib), CAS No. 1448347 49 6, is a potent, selective and reversible inhibitor of IDH1 with IC50 < 100 nM. It has been shown to lower 2 HG levels and restore cellular differentiation in IDH1 mutant primary human blast cells cultured ex vivo. In phase I clinical trials targeting patients with IDH1 mutated, relapsed and or refractory (R R) AML or untreated AML not eligible for standard of care or R R MDS, AG 120 is well tolerated to date (10
US$ 14.13
US$ 570.00
US$ 375.00
US$ 185.00
US$ 190.00